
|Videos|March 6, 2014
Potential Biomarkers in Prostate Cancer
Author(s)Leonard Gomella, MD
Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the future of biomarkers in prostate cancer that might complement or displace PSA.
Advertisement
Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the future of biomarkers in prostate cancer that might complement or displace PSA.
Clinical Pearls:
- There are a large number of genomic markers being looked at such as specific genetic alterations in circulating tumor cells
- These potential biomarkers are still being researched but are providing prognostic information and genomic information
- Although many biomarkers are being researched, none yet have the potential to displace PSA
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
4
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
5



















